Baidu
map

Chest:传统香烟与电子烟对氧化应激和血管功能的影响

2016-10-02 xing.T MedSci原创

由此可见,单次吸食香烟对氧化应激标志物和血流介导的血管扩张程度的就会产生不利影响,尽管电子香烟似乎影响较。但是,吸电子香烟对血管的慢性影响进行进一步的研究是很有必要的。

人们在戒烟过程中,很多人选择通过先用电子烟来替代真正的烟草,达到缓慢的戒烟效果。然而,电子烟的血管安全性尚未澄清。最近,呼吸疾病领域权威杂志《Chest》杂志发表了一篇旨在比较电子烟与传统香烟对健康吸烟者和不吸烟成年人氧化应激和血管内皮功能的影响。

研究者采用交叉、单盲的研究,纳入了40名健康受试者(20吸烟者和20名不吸烟者,两组研究对象年龄和性别相匹配)。首先,所有受试者都吸传统香烟,一个星期后,所有吸香烟者改吸相同尼古丁含量的电子烟。研究对象在吸烟前和吸烟后采集血液样本,并测量氧化应激标志物、一氧化氮的生物利用度、维生素E水平以及血流介导的血管扩张程度。

研究者发现:吸传统香烟和电子烟都可导致可溶性NOX2衍生肽和8-异前列腺素F2α水平显著升高,而一氧化氮的生物利用度、维生素E水平以及血流介导的血管扩张程度显著下降。广义估计方程分析证实,氧化应激标志物和血流介导的血管扩张程度受吸烟的影响显著,而研究结果表明电子香烟与传统香烟对维生素E水平(P=0.413)以及血流介导的血管扩张程度(P=0.311)的生物学效应的影响均无统计学差异。然而,电子香烟似乎比传统香烟对可溶性NOX2衍生肽(P=0.001)、8-异前列腺素F2α(P=0.046)和一氧化氮的生物利用度(P=0.001)的水平影响较小。

由此可见,单次吸食香烟对氧化应激标志物和血流介导的血管扩张程度就会产生不利影响,尽管电子香烟似乎影响较小。但是,吸电子香烟对血管的慢性影响进行进一步的研究很有必要。

原始出处:

Roberto Carnevale. et al. Acute Impact of Tobacco vs Electronic Cigarette Smoking on Oxidative Stress and Vascular Function. Chest. 2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929260, encodeId=03d2192926037, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 12 02:02:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050567, encodeId=ce26205056eeb, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Dec 02 03:02:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141309, encodeId=d38e141309c6, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Oct 06 20:50:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372842, encodeId=f89c13e2842fd, content=<a href='/topic/show?id=63ff1014107e' target=_blank style='color:#2F92EE;'>#香烟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101410, encryptionId=63ff1014107e, topicName=香烟)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445130, encodeId=aa4d14451303a, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511969, encodeId=ace1151196969, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2017-05-12 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929260, encodeId=03d2192926037, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 12 02:02:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050567, encodeId=ce26205056eeb, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Dec 02 03:02:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141309, encodeId=d38e141309c6, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Oct 06 20:50:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372842, encodeId=f89c13e2842fd, content=<a href='/topic/show?id=63ff1014107e' target=_blank style='color:#2F92EE;'>#香烟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101410, encryptionId=63ff1014107e, topicName=香烟)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445130, encodeId=aa4d14451303a, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511969, encodeId=ace1151196969, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929260, encodeId=03d2192926037, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 12 02:02:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050567, encodeId=ce26205056eeb, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Dec 02 03:02:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141309, encodeId=d38e141309c6, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Oct 06 20:50:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372842, encodeId=f89c13e2842fd, content=<a href='/topic/show?id=63ff1014107e' target=_blank style='color:#2F92EE;'>#香烟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101410, encryptionId=63ff1014107e, topicName=香烟)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445130, encodeId=aa4d14451303a, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511969, encodeId=ace1151196969, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-06 忠诚向上

    好好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1929260, encodeId=03d2192926037, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 12 02:02:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050567, encodeId=ce26205056eeb, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Dec 02 03:02:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141309, encodeId=d38e141309c6, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Oct 06 20:50:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372842, encodeId=f89c13e2842fd, content=<a href='/topic/show?id=63ff1014107e' target=_blank style='color:#2F92EE;'>#香烟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101410, encryptionId=63ff1014107e, topicName=香烟)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445130, encodeId=aa4d14451303a, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511969, encodeId=ace1151196969, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929260, encodeId=03d2192926037, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 12 02:02:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050567, encodeId=ce26205056eeb, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Dec 02 03:02:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141309, encodeId=d38e141309c6, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Oct 06 20:50:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372842, encodeId=f89c13e2842fd, content=<a href='/topic/show?id=63ff1014107e' target=_blank style='color:#2F92EE;'>#香烟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101410, encryptionId=63ff1014107e, topicName=香烟)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445130, encodeId=aa4d14451303a, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511969, encodeId=ace1151196969, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1929260, encodeId=03d2192926037, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Fri May 12 02:02:00 CST 2017, time=2017-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050567, encodeId=ce26205056eeb, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Dec 02 03:02:00 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141309, encodeId=d38e141309c6, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Thu Oct 06 20:50:05 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372842, encodeId=f89c13e2842fd, content=<a href='/topic/show?id=63ff1014107e' target=_blank style='color:#2F92EE;'>#香烟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101410, encryptionId=63ff1014107e, topicName=香烟)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445130, encodeId=aa4d14451303a, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511969, encodeId=ace1151196969, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Oct 04 14:02:00 CST 2016, time=2016-10-04, status=1, ipAttribution=)]

相关资讯

PLoS One:中国吸烟人群对电子烟的认识情况

目前电子烟的使用率越来越高。研究者对中国香港每天吸烟的人群进行了一项研究,探究他们对电子烟在戒烟方面的认识、使用和感知到的有效性。该研究在2014年纳入了1307名每天吸烟的研究对象。在纳入研究以及随访1周后,报道以下几方面情况:社会人口统计学特征、平时的吸烟状况、烟瘾情况、尝试戒烟、戒烟意愿、对电子烟的认识、使用、感觉到的戒烟有效性。通过多因素分析识别与戒烟过程中,电子烟的认识、使用以及感觉到的

Nature:挥之不去的电子烟迷雾

在合理监管的前提下,电子烟可能是个好东西;但很显然,目前电子烟正在导致越来越多的青少年使用尼古丁,使得他们染上烟瘾。 在很多方面,现代电子烟和其“前身”并没有很大区别。它又被称作个人喷雾器或电子尼古丁传输系统,可能是公共卫生研究人员在烟草控制中面临的最具破坏性的设备。一些人担心,电子烟的出现会延续吸烟这一习惯,破坏数十年烟草防控的努力。 现在,曾经团结一致反对烟草的组织出现了分歧。烟草研究者、

电子烟中的致癌化合物含量比普通香烟低

一项新的研究表明,与普通香烟相比,电子香烟能够为人们带来相同含量的尼古丁,但电子烟中的毒素、致癌物质含量降低了。“这项研究表明:对吸烟者来说,完全停止接触普通香烟,投入电子香烟的怀抱,可能能够显着减少人体与很多致癌物质的接触机会,”该研究的作者 Maciej Goniewicz 表示,他是纽约布法罗罗斯威尔帕克癌症研究所肿瘤学助理教授。在该项研究中,研究者们招募了20名成年人,他们每天都会吸烟,并

Addiction:新方法测量电子烟的尼古丁递送量

电子烟(e-cigarettes)替代烟草香烟的有效性可能取决于它们能否持续提供吸烟者所需的尼古丁量,从而抵制回归传统香烟的欲望。 在最新发表于《Addiction》期刊的研究中,研究人员评估了一种测量电子烟尼古丁递送量的新方法。研究发现,使用"cartomizers(烟弹+雾化器)"的第一代电子烟,在尼古丁递送方面始终低于使用"atomizers(烟油雾化器)"的后一代电子烟。后一代电子烟能

J Mol Med:电子香烟削弱机体免疫系统

在美国,高中学生中使用电子烟的人数比重从2013年的4.5%到2013年的13.4%已经增长了近三倍,中学生的吸烟比重从2013年的1.1%到2014年的3.9%,超过青少年吸烟的比例。25-44岁的民众中,有20%的美国人抽电子烟。 当青少年因为时尚和潮流吸烟时,之前吸烟的烟民已经开始戒烟。有研究报道,许多青少年吸电子烟之后1年便开始吸香烟。使用电子烟增加了他们呼吸道和免疫系统受损的风险,同时也

英政府在争议声中为电子烟颁发戒烟辅助认证

尽管学术界对电子烟的健康危害程度是否低于普通香烟仍存较大争议,英国药品与保健品管理局近日还是给英美烟草公司一款电子烟产品发出认证,允许这款产品以戒烟辅助工具的身份在市场上销售。这款电子烟产品在获得药品与保健品管理局认证后,就有可能像其他尼古丁替代品那样,作为英国公共医疗体系中合法的戒烟治疗辅助手段来使用。英国公共医疗体系的统计数据显示,那些同时使用电子烟和其他治疗方式的吸烟人士中,三分之二的人在一

Baidu
map
Baidu
map
Baidu
map